In accord, flow cytometry analysis illustrated that TAMs from tumor-bearing Irg1−/− mice manifested enhanced immunogenic antigen presentation, as evidenced by higher expression of cell surface markers, such as MHC-I, MHC-II, or Cd40 (Fig. 3C). This evidence concerns the gene CD40 and neoplasm.